Clinical Trial

FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 20, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with standard first-line therapy to enhance the anti-tumor immune effect at the same time, thereby extending the progression-free survival of patients and improving the prognosis of patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-06.
Status change: Not Yet Recruiting → Recruiting 2024-12-18
Trial Details
NCT Number NCT06403111
Lead Sponsor Changzhou No.2 People's Hospital
Conditions Non-small Cell Lung Cancer
Enrollment 62 participants
Start Date 2024-06-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-20